
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics has demonstrated strong financial performance in F2Q25, with all product lines in the Med Tech segment reporting impressive growth, including notable increases for Auryon (21.8%), AngioVac (50.7%), and AlphaVac (33.3%). The recent FDA clearance of the NanoKnife System for prostate tissue ablation positions the company for potential expansion in the Med Tech market, utilizing its innovative irreversible electroporation technology that offers a minimally invasive treatment option. This positive momentum, bolstered by increased FY25 adjusted EBITDA guidance and the anticipated favorable results from ongoing clinical trials, underscores AngioDynamics's strengthening market position and growth potential.
Bears say
AngioDynamics Inc. faces several significant risks that contribute to a negative outlook, including lower-than-expected growth in Med Tech revenue and potential divestiture of Med Device products, which have already shown a notable decline in sales. The company reported an adjusted net loss of $1.7 million as well as a pro forma year-over-year decline in actual sales, indicating challenges in maintaining profitability despite a modest growth in net sales. Furthermore, competition is increasing, and concerns regarding potential dilution risk add to the uncertainty surrounding the company's financial stability and future performance.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares